Clinical trials
catalyst calendar across sponsors →Studies where NKTX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional
Held by 13 tracked-famous managers (CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC, AQR CAPITAL MANAGEMENT LLC, MARSHALL WACE, LLP, +8 more) · FINRA short interest 5.3 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)NCT06733935Incidence of Dose-limiting toxicities (DLTs) [Safety and Tolerability]Open-label · Treatment | Phase 1/2 | Recruiting | Drug: NKX019, Fludarabine, Cyclophosphamide | Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis | 240 | Oct 2028 | ≤ 803 d | 2026-08-07 |
| A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)NCT06557265Incidence of dose-limiting toxicities (DLTs) [Safety and Tolerability]Open-label · Treatment | Phase 1/2 | Recruiting | Drug: NKX019, Fludarabine, Cyclophosphamide | Lupus Nephritis, Primary Membranous Nephropathy | 120 | Apr 2027 | ≤ 253 d | 2026-06-04 |
| NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell CancersNCT05020678Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Open-label · Treatment | Phase 1 | Active, not recruiting | Biological: NKX019 | Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma, Large-cell Lymphoma | 150 | 2025-03-31actual | — | 2026-04-20 |
| NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDSNCT04623944Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Open-label · Treatment | Phase 1 | Active, not recruiting | Biological: NKX101 - CAR NK cell therapy | Relapsed/Refractory AML, AML, Adult, MDS, Refractory Myelodysplastic Syndromes | 61 | 2024-10-02actual | — | 2024-12-27 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19